Stockscreener 앱 받기
0.923
3.17%
-0.0302
시간 외 거래:
.95
0.027
+2.93%
전일 마감가:
$0.9532
열려 있는:
$0.92
하루 거래량:
3.64M
Relative Volume:
7.87
시가총액:
$75.23M
수익:
$3.91M
순이익/손실:
$-206.53M
주가수익비율:
-0.2425
EPS:
-3.8057
순현금흐름:
$-167.78M
1주 성능:
-7.70%
1개월 성능:
-5.82%
6개월 성능:
-45.38%
1년 성능:
-38.87%
1일 변동 폭
$0.91
$0.95
1주일 범위
$0.8995
$1.01
52주 변동 폭
$0.8989
$2.5362
I Mab Adr Stock (IMAB) Company Profile
IMAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMAB
I Mab Adr
|
0.923 | 75.23M | 3.91M | -206.53M | -167.78M | -2.4825 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-09 | 개시 | Siebert Williams Shank | Buy |
| 2021-06-02 | 개시 | Daiwa Securities | Buy |
| 2021-03-15 | 개시 | Needham | Buy |
| 2021-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-25 | 개시 | Piper Sandler | Overweight |
| 2020-12-07 | 개시 | H.C. Wainwright | Buy |
| 2020-07-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-12 | 개시 | China Renaissance | Buy |
| 2020-02-11 | 개시 | Jefferies | Buy |
모두보기
I Mab Adr 주식(IMAB)의 최신 뉴스
I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies - MSN
I-Mab names Sean Fu as new CEO - Investing.com India
Invitation: Vallourec Q3 2024 Results ReleaseConference Call on Friday, November 15, 2024 - The Manila Times
I-Mab ADR (NASDAQ: IMAB) Stock: Investors Need To Know This - Stocks Register
Would I Buy Spectral AI Inc (NASDAQ: MDAI) Stock At Any Time In The Future? - Stocks Register
If You Don’t Buy Hub Cyber Security Ltd (NASDAQ: HUBC) Now, You’ll Kick Yourself Later - Stocks Register
Itau Unibanco Holding S.A. ADR (NYSE: ITUB) Still Pointing Upwards - Stocks Register
Is Veritone Inc’s (NASDAQ:VERI) Stock On The Decline? - Stocks Register
Cisco Systems, Inc. (NASDAQ: CSCO): What’s Next After The Stock Plunge? - Stocks Register
Should This Give Tandem Diabetes Care Inc (NASDAQ: TNDM) Investors Sleepless Nights? - Stocks Register
Kinross Gold Corp. (NYSE: KGC) Investors Should Be Worried About This. - Stocks Register
Where Do Analysts See Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Heading? - Stocks Register
Not A Good News For Keycorp (NYSE: KEY): The Stock Could Go Down -34.98 Percent More - Stocks Register
Analyst Forecast For Grab Holdings Limited (NASDAQ: GRAB) - Stocks Register
Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading - MSN
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
IMAB’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Company’s Banking Shares: Up -42.43% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
It makes sense and dollars to buy I-Mab ADR (IMAB) stock - SETE News
Ratio Revelations: I-Mab ADR (IMAB)’s Financial Metrics in the Spotlight - The Dwinnex
I-Mab ADR (IMAB) Stock: From Low to High in 52 Weeks - The InvestChronicle
IMAB’s price-to-sales ratio: A comparative analysis with its peers - US Post News
Piper Sandler maintains Overweight rating on I-Mab stock on drug data - Investing.com
I-Mab reveals Phase 1 data for lung cancer treatment - Investing.com
Federal Hill Taphouse & Kitchen abruptly closes - WPRI.com
I-Mab ADR (IMAB)’s stock price in review: A technical analysis - US Post News
There is no doubt that I-Mab ADR (IMAB) ticks all the boxes. - SETE News
Earnings call: I-MAB Biopharma discusses pipeline progress and financials - Investing.com India
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates - PR Newswire
Insight venture partners executives sell over $61 million in nCino shares By Investing.com - Investing.com India
I-Mab appoints new chairman and interim CEO - Investing.com
2024-07-15 | I-Mab Announces Leadership Transitions | NDAQ:IMAB | Press Release - Stockhouse Publishing
Financial Health Report: I-Mab ADR (IMAB)'s Ratios Tell a Tale – DWinneX - The Dwinnex
Teva Acquires Rights to Oncology Biosimilar Candidates - Yahoo News UK
I-Mab announces clinical trial collaboration with Bristol Myers - TipRanks
Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks - Yahoo Movies UK
I-Mab Finalizes Divestiture and Resolves ObligationsTipRanks.com - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature.com
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 - PR Newswire
Effects of a monoclonal antibody against (pro)renin receptor on gliomagenesis - Nature.com
Market Brief: Will the December CPI Report Help Further Tame Inflation Fears? - Morningstar
Morningstar’s Best- and Worst-Performing Stocks: 2022 - Morningstar
The Cheapest Stock in the World - Morningstar.ca
10 of the Cheapest Stocks of 2022 - Morningstar
Why Are Some China Healthcare Stocks Up 50%? - HK.Morningstar.com
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage - Nature.com
The Best- and Worst-Performing Stocks: Q3 2022 - Morningstar
I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal - Yahoo New Zealand News
Markets Brief: How High Can Mortgage Rates Go? - Morningstar
I Mab Adr (IMAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):